FD Neurotechnologies Consulting & Services, Inc.

FD Neurotechnologies Consulting & Services, Inc., headquartered in Columbia, Maryland, is a minority-owned, self-certified small disadvantaged business specializing in advanced histological and neurohistological laboratory services to support federal medical research and healthcare initiatives. As a registered federal contractor and grant recipient since 2009, the company provides specialized tissue analysis, preparation, and staining services essential to neuroscience research, neuropathology studies, and neurological disease investigation. FD Neurotechnologies leverages state-of-the-art drug discovery tools and techniques, positioning itself as a preferred provider of specialized scientific research services across multiple federal healthcare and research agencies.

Through federal contract awards, FD Neurotechnologies has demonstrated extensive expertise delivering histological and neurohistological services to the Defense Health Agency, Centers for Disease Control and Prevention, and Veterans Affairs. The company has received multiple delivery orders from the Defense Health Agency ranging from $10,905.06 to $47,111.42 for tissue section staining, neuropathology research support, and neurohistological services to meet data milestones for funded research projects, including support for National Institutes of Health research initiatives. Additionally, FD Neurotechnologies has provided neurohistological staining services to the CDC Pittsburgh, including silver degeneration, tyrosine hydroxylase, and GFAP staining for research investigating pesticide exposure and parkinsonism susceptibility, as well as preparation and testing of rat brain tissue valued at $83,454.52. The company also received a purchase order from Veterans Integrated Service Network 8 for rat cerebrum services. Notably, one CDC contract valued at $25,858.02 was set aside for small businesses under NAICS code 541690 Other Scientific and Technical Consulting Services, though the majority of FD Neurotechnologies' contract awards were awarded on competitive grounds without set-aside designations, reflecting the company's specialized capabilities in advanced laboratory services.

FD Neurotechnologies has received federal grant funding through the National Institute on Aging for a Project Grant focused on neuroscience and pharmaceutical research. The grant award, initiated September 1, 2021 and completed August 31, 2023, supported the discovery and development of novel phosphodiesterase-2A (PDE2A) inhibitors to treat memory deficits associated with mild cognitive impairment and Alzheimer's disease. Under this grant, FD Neurotechnologies collaborated with the University at Buffalo and the University of Arizona to discover and optimize novel drug-like inhibitors of PDE2A and evaluate their pharmacological effects in cell and animal models. The grant leveraged the company's expertise in medicinal chemistry, drug discovery, and PDE-related pharmacology to advance potential clinical candidates for treating cognitive disorders affecting millions of patients with minimal current therapeutic options.

FD Neurotechnologies maintains two active federal contract indefinite delivery vehicles that establish streamlined procurement mechanisms for federal agencies requiring specialized histological services. The primary vehicle is a single-award indefinite delivery contract with the Defense Health Agency valued at $749,458.50, effective through August 6, 2028, which provides a framework for recurring procurement of histology services, neurohistological staining, tissue section preparation, and neurological sample analysis. Between March 2024 and September 2025, the Defense Health Agency issued seven delivery orders totaling approximately $149.1 million in obligations against this contract, with individual task orders ranging from $11,380.48 to $47,111.42 and completion dates through September 30, 2025. The second vehicle is a single-award Blanket Purchase Agreement with the Department of Veterans Affairs valued at $225,000, awarded July 15, 2024 and effective through July 14, 2027, which streamlines procurement of histology slides and accessories for the VA White River Junction Healthcare System. Together, these indefinite delivery vehicles position FD Neurotechnologies as a preferred provider of specialized histological and neurohistological services supporting federal medical research and healthcare operations across the Defense Health Agency and Veterans Affairs.